A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

March 31, 2009

Study Completion Date

October 31, 2010

Conditions

Myelodysplastic SyndromesThrombocytopenia

Interventions

BIOLOGICAL

AMG 531

AMG 531 will be administered by subcutaneous injection at a dose of 500 or 750 μg.

DRUG

Placebo

Subjects in the control group will receive placebo via subcutaneous injection.